Medical Condition News

RSS

Researchers identify new class of compounds that inhibit spread of prions

A team of University of Alberta researchers has identified a new class of compounds that inhibit the spread of prions, misfolded proteins in the brain that trigger lethal neurodegenerative diseases in humans and animals.

24 Jul 2012

New laser technology can non-invasively destruct cancerous tumors

Researchers at the Center for Laser Applications at the University of Tennessee Space Institute in Tullahoma have developed a technology that goes on a "seek and destroy" mission for cancerous tumors. They have harnessed the power of lasers to find, map and non-invasively destruct cancerous tumors.

24 Jul 2012

Two thirds of obese children have heart disease risk factors

Two out of three severely obese kids already have at least one risk factor for heart disease, suggests research published online in Archives of Disease in Childhood.

24 Jul 2012

Aspirin use appears to reduce risk of Barrett's esophagus

Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

24 Jul 2012

UV induction of melanin is directly involved in melanoma formation

A new study conducted by GW School of Medicine and Health Sciences (SMHS) researchers Edward C. De Fabo, Ph.D., Frances P. Noonan, Ph.D., and Anastas Popratiloff, M.D., Ph.D., has been published in the journal Nature Communications. Their paper, entitled "Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment," was published in June 2012.

24 Jul 2012

Study reveals 50% increased risk of urothelial and colorectal cancers in adulthood

Parents are increasingly conscious of the dangers of childhood obesity. There is a growing recognition of health problems associated with extra pounds, including the risk of diabetes, heart disease, and joint and muscle pain.

24 Jul 2012

Top-line result from Pfizer Bapineuzumab Phase 3 studies on Alzheimer's

Elan Corporation, plc announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.

24 Jul 2012

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes.

24 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

Ocular Therapeutix announces results from sustained release OTX-TP1 study on glaucoma

Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Scientists demonstrate link between cancer and faulty differentiation of stem cells

Stem cells hold great promise for the medicine of the future, but they can also be a cause of disease. When these self-renewing, unspecialized cells fail to differentiate into diverse cell types, they can start dividing uncontrollably, leading to cancer. Already several decades ago, Weizmann Institute scientists were among the first to demonstrate the link between cancer and the faulty differentiation of stem cells. Now a new Weizmann Institute-led study, published in Molecular Cell, reveals a potential molecular mechanism behind this link.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

InnerSpace Neuro introduces new Tunneled Ventricular Catheter for TBI

InnerSpace Neuro, Inc., developer of the Hummingbird family of products used to treat Traumatic Brain Injury (TBI), today reported that an abstract featuring its Hummingbird SynergyDuo Ventricular Catheter is being presented at the Neurotrauma 2012 meeting in Phoenix, Arizona. The company also announced launch of its new Tunneled Ventricular Catheter.

23 Jul 2012

Neural precursor cells suppress aggressive tumors

Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors.

23 Jul 2012

Synthetic triterpenoids block development of Parkinson's disease

A new and powerful class of antioxidants could one day be a potent treatment for Parkinson's disease, researchers report.

23 Jul 2012

Tiny microneedles to treat macular degeneration

Thanks to tiny microneedles, eye doctors may soon have a better way to treat diseases such as macular degeneration that affect tissues in the back of the eye. That could be important as the population ages and develops more eye-related illnesses - and as pharmaceutical companies develop new drugs that otherwise could only be administered by injecting into the eye with a hypodermic needle.

23 Jul 2012

Once-daily Gralise significantly reduces pain intensity in PHN patients

Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).

23 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012